Purple biotech announces initiation of part 2 of ongoing phase 1/2 clinical trial evaluating nt219 for treatment of multiple cancers supporting potential expansion of clinical program

Part 2 is a dose escalation study of nt219, in combination with cetuximab (erbitux ® ), in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck cancer or colorectal adenocarcinoma

PPBT Ratings Summary

PPBT Quant Ranking